TrialArthritis & rheumatology (Hoboken, N.J.)2016

Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate.

Mark C Genovese et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.